Previous 10 | Next 10 |
Heron Therapeutics ( NASDAQ: HRTX ) on Thursday said it was planning to reduce its employee headcount by 34% as part of a restructuring and cost reduction plan. The plan also includes reductions and reallocations to the company's overall sales, general and administrati...
Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability PR Newswire - Changes result in annualized cost savings of $43M , extending the cash runway; Company is continuing to reduce exter...
The most heavily shorted names have been rallying off their lows in the past several days. On a relative basis, the 100 most heavily shorted stocks versus the Russell 3,000 have broken out of the downtrend that has been in place since the height of the meme stock mania in January 2021...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty PR Newswire SAN DIEGO , June 14, 202...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Heron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference PR Newswire SAN DIEGO , May 26, 2022 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patie...
Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting PR Newswire - New interim data from Phase 2 study suggests ZYNRELEF was well-tolerated and may effectively manage postpartum pain and minimize p...
Heron Therapeutics, Inc. (HRTX) Q1 2022 Results Conference Call May 09, 2022 04:30 PM ET Company Participants David Szekeres - EVP and COO Barry Quart - Chairman and CEO John Poyhonen - President and Chief Commercial Officer Kimberly Manhard - EVP, Drug Development and Board Director Conferen...
Heron Therapeutics press release (NASDAQ:HRTX): Q1 GAAP EPS of -$0.63 misses by $0.15. Revenue of $23.46M (+17.2% Y/Y) beats by $0.85M. For further details see: Heron Therapeutics GAAP EPS of -$0.63 misses by $0.15, revenue of $23.46M beats by $0.85M
News, Short Squeeze, Breakout and More Instantly...
Heron Therapeutics Inc. Company Name:
HRTX Stock Symbol:
NASDAQ Market:
Heron Therapeutics Inc. Website:
Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System PR Newswire SAN DIEGO , July 15, 2024 /PRNewswire/ -- Heron Therapeutics, Inc....
Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire -The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024 ...
Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") PR Newswire SAN DIEGO , May 29, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechn...